KPTI · Karyopharm Therapeutics Inc.
$2.00
+0.09 (+4.45%)
At close · Aug 6
Going-concern doubt
— flagged May 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on our current business plan and current capital resources, combined with the uncertainty regarding the availability of additional funding or other strategic alternatives and considering our debt service obligations and financial covenant to maintain minimum liquidity, we have concluded that there is substantial doubt regarding our ability to continue as a going concern within one year after the date the accompanying condensed consolidated financial statements are issued.”View the 10-Q filed May 14, 2026
Market Cap
$43.29M
Shares
22.66M
Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
Equity Offering (ATM) Programs
| Program Established | Capacity | Remaining | As of | Runs Through | Source |
|---|---|---|---|---|---|
| 2023-02-17 | $100,000,000 | $100,000,000 | 2025-06-30 | — | 10-Q , filed 2025-08-11 |
Key facts
CIK
1503802
CUSIP
48576U205
13F (30d)
14 filings
14 filers
Visit website
Investor relations